NCT03203681View on ClinicalTrials.gov

Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 27, 2017

Primary Completion Date

June 1, 2020

Study Completion Date

June 1, 2020

Conditions
Hypogonadism, Male
Interventions
DRUG

Natesto

4.5% nasal testosterone. 11.0 mg testosterone administered per dose (2 pump actuations, 1 pump per nostril) applied intranasally three times a day.

Trial Locations (1)

33136

University of Miami, Miami

Sponsors
All Listed Sponsors
collaborator

Acerus Pharmaceuticals Corporation

INDUSTRY

lead

University of Miami

OTHER